White Paper

Harnessing Integrated Preclinical Solutions to Accelerate Bispecific Antibody Development

Bispecific antibodies (BsAbs) represent a major advancement in cancer therapy, combining the targeting precision of monoclonal antibodies with the ability to engage multiple tumor antigens simultaneously. This dual-targeting capability not only enhances therapeutic efficacy but also minimizes off-target effects and reduces the potential for drug resistance. This white paper explores the clinical landscape of anti-cancer BsAbs and different preclinical solutions for accelerating the development of this specific drug modality. Finally, this white paper includes a case study on preclinical assessment to Investigational New Drug (IND) for the HX009 BsAb and describes the various preclinical models and strategies for testing efficacy and safety.

Download this White Paper to Discover:

• How to overcome the challenges of BsAbs: Learn about the advancements in protein/antibody engineering that address traditional development challenges of BsAbs, and explore the potential of these innovative therapies in oncology.
  
  
• Innovative drug development strategies: Discover the integrated approach to preclinical solutions that significantly expedites the development of BsAbs, ensuring thorough characterization and efficacy.
  
  
• Preclinical case study: Gain insights from a comprehensive case study of HX009, highlighting the integrated in vitro and in vivo solutions that supported its FDA IND application.

Download the White Paper Now!